Please use this identifier to cite or link to this item: https://doi.org/10.1158/1078-0432.CCR-13-1354
Title: AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer
Authors: Dunne, P.D.
McArt, D.G.
Blayney, J.K.
Kalimutho, M.
Greer, S.
Wang, T. 
Srivastava, S. 
Ong, C.W. 
Arthur, K.
Loughrey, M.
Redmond, K.
Longley, D.B.
Salto-Tellez, M.
Johnston, P.G.
Van Schaeybroeck, S.
Issue Date: 1-Jan-2014
Source: Dunne, P.D., McArt, D.G., Blayney, J.K., Kalimutho, M., Greer, S., Wang, T., Srivastava, S., Ong, C.W., Arthur, K., Loughrey, M., Redmond, K., Longley, D.B., Salto-Tellez, M., Johnston, P.G., Van Schaeybroeck, S. (2014-01-01). AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clinical Cancer Research 20 (1) : 164-175. ScholarBank@NUS Repository. https://doi.org/10.1158/1078-0432.CCR-13-1354
Abstract: Purpose: Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse. Thus, novel therapeutic strategies are needed for early-stage colorectal cancer. Residual micrometastatic disease from the primary tumor is a major cause of patient relapse. Experimental Design: To model colorectal cancer tumor cell invasion/metastasis, we have generated invasive (KRASMT/KRASWT/+chr3/p53-null) colorectal cancer cell subpopulations. Receptor tyrosine kinase (RTK) screens were used to identify novel proteins that underpin the migratory/invasive phenotype. Migration/invasion was assessed using the XCELLigence system. Tumors from patients with early-stage colorectal cancer (N = 336) were examined for AXL expression. Results: Invasive colorectal cancer cell subpopulations showed a transition from an epithelial-tomesenchymal like phenotype with significant increases in migration, invasion, colony-forming ability, and an attenuation of EGF receptor (EGFR)/HER2 autocrine signaling. RTK arrays showed significant increases in AXL levels in all invasive sublines. Importantly, 5-FU treatment resulted in significantly increased migration and invasion, and targeting AXL using pharmacologic inhibition or RNA interference (RNAi) approaches suppressed basal and 5-FU-induced migration and invasion. Significantly, high AXL mRNAand protein expression were found to be associated with poor overall survival in early-stage colorectal cancer tissues. Conclusions: We have identified AXL as a poor prognostic marker and important mediator of cell migration/invasiveness in colorectal cancer. These findings provide support for the further investigation of AXL as a novel prognostic biomarker and therapeutic target in colorectal cancer, in particular in the adjuvant disease in which EGFR/VEGF-targeted therapies have failed. Clin Cancer Res; 20(1); 164-75. © 2013 AACR.
Source Title: Clinical Cancer Research
URI: http://scholarbank.nus.edu.sg/handle/10635/116236
ISSN: 10780432
DOI: 10.1158/1078-0432.CCR-13-1354
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

45
checked on Feb 15, 2018

WEB OF SCIENCETM
Citations

39
checked on Jan 30, 2018

Page view(s)

54
checked on Feb 19, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.